<DOC>
	<DOC>NCT01267279</DOC>
	<brief_summary>In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery.</brief_summary>
	<brief_title>Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients undergoing primary elective total hip replacement Osteoporosis (BMD â‰¤2.5) Trauma to the operated femur, hip revisions, femoral dysplasia, trochanteric osteotomy, inflammatory arthritis Severe renal impairment Use of any medications affecting BMD Known sensitivity to bisphosphonates Severe dental problems, and pregnancy or being able to conceive and not using reliable birth control methods</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>